Last reviewed · How we verify
NCT03986541
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
trial testing Immunohistochemistry in Colorectal Cancer Stage IV in 541 participants. Completed in 22 July 2022.
22 February 2022
Quick facts
| Lead sponsor | University of Leeds |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 541 |
| Start date | 23 September 2019 |
| Primary completion | 22 February 2022 |
| Estimated completion | 22 July 2022 |
| Sites | 7 locations across United Kingdom |
Drugs / interventions tested
- Immunohistochemistry — full drug profile →
Conditions studied
- Colorectal Cancer Stage IV — all drugs for Colorectal Cancer Stage IV →
Sponsor
University of Leeds
Who can join
18 and older, any sex, with Colorectal Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational study investigating the relationship between tumour amphiregulin, epiregulin and epithelial growth factor receptor expression and response to anti-EGFR agents in advanced colorectal cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.
Randon G, Maddalena G, Germani MM, Pircher CC, et al · · 2022 · cited 33× · PMID 35544729 · DOI 10.1200/po.22.00037
Verify or expand the search:
- PubMed search for NCT03986541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunohistochemistry
Trials testing the same drug.
- NCT07319130 — Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 Exp · NA · enrolling by invitation
- NCT07069842 — The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes · recruiting
- NCT06657755 — Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients · completed
- NCT06485193 — The Innate Immune Response and Enteric Nervous System in Crohn's Disease. · terminated
- NCT05553080 — Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma · completed
Other recruiting trials for Colorectal Cancer Stage IV
Currently open trials in the same condition.
- NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
- NCT06342401 — Early Onset Colorectal Cancer Detection · recruiting
- NCT05426005 — Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer · Phase 1, PHASE2 · recruiting
- NCT05576896 — Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-muta · Phase 2 · recruiting
- NCT05171660 — Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer · Phase 3 · active not recruiting
Other University of Leeds trials
Trials by the same sponsor.
- NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
- NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
- NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
- NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
- NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03986541 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Leeds
- Last refreshed: 28 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing